Ann: Medlab Progresses Nasdaq Dual Listing, page-7

I just think market is more interested in companies that are not going for registered medicines, like CAU. Even with mega buyouts of companies like GW Pharma, market seems to be more interested in the market fluff 'non registered medicine' companies.

Even with unlawful advertising and fines MXC, LGP still worth several multiples of MDC, despite playing the game correctly and going for an approved medicine. At this stage MDC is worthless when comparing to MXC and CAU. Look at the market cap differences. MDC is at the bottom despite doing the most thorough and successful work. Look at BOT, went for claimed acne cure with a cream, failed miserably. and still worth 3-4 times more than MDC that succeeding in its work on chronic cancer pain with Nanabis.

So ones fails and succeeds with value(BOT), the other succeeds but fails in value (MDC). What a weird concept.